Explanipedia

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM) Open

Narendranath Epperla, Yizhe Xu, Daniel A. Ermann, Lapo Alinari · 2025

Background: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma (NHL) with an aggressive disease course in the majority of cases. While BTK inhibitors (BTKis) have markedly improved the outcomes in relapsed or refractory…

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy Open

Rushir J. Choksi, Xiaogang Wang, Beverly Chigarira, Lindsay Aton, Daniel A. Ermann · 2025

Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated clinical efficacy in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Zanubrutinib is a highly specific and potent next-generation BTK inhibito…

838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES Open

Alexey V. Danilov, Michael Tees, H. A. Shah, Clare Sun, Ian W. Flinn , et al. · 2025

504 | IMPACT OF THE NEUTROPHIL/LYMPHOCYTE RATIO ON OUTCOMES FOLLOWING BISPECIFIC ANTIBODY THERAPY IN RELAPSED/REFRACTORY LYMPHOMA PATIENTS Open

Allison M. Bock, Kelly Glazer Baron, Courtney L. Wagner, Lindsey Fitzgerald, Daniel A. Ermann , et al. · 2025

620 | A STANDARDIZED PROCESS FOR A RAPID DOSE ESCALATION OF EPCORITAMAB FOR PATIENTS WITH LYMPHOID MALIGNANCIES IN THE UNITED STATES Open

Kelly Glazer Baron, Courtney L. Wagner, L. A. Fitzgerald, Daniel A. Ermann, Boyu Hu , et al. · 2025

Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens Open

Kelsey Baron, Eric Anto, John Esther, Victoria A. Vardell, Lisa Pappas , et al. · 2025

In conclusion, this study of real-world patients supports the use of BR and rituximab maintenance for front-line treatment of FL. Further prospective studies are needed to determine the ideal treatment for FL G3A.

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL Open

Jacob D. Soumerai, Jacqueline C. Barrientos, Inhye E. Ahn, Catherine C. Coombs, Douglas E. Gladstone , et al. · 2024

Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are comme…

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL Open

Jacob D. Soumerai, Jacqueline C. Barrientos, Inhye E. Ahn, Catherine C. Coombs, Douglas E. Gladstone , et al. · 2024

Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are com…

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study Open

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps , et al. · 2024

Background: In TRANSCEND CLL 004 (NCT03331198),monotherapy with liso-cel, an autologous, CD19-directed CAR T cell product (100 × 106 CAR+ T cells [dose level (DL) 2]), resulted in 43% ORR and 18% CR/CR with incomplete marrow recovery (CRi)…

Characterization of BTK mutation pathologic status and association with known prognostic mutations (TP53, ATM, BIRC3, SF3B1, NOTCH1) in CLL: An AACR Project GENIE Analysis Open

Andrew A. Pierce, Daniel A. Ermann · 2024

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study Open

Laura Samples, Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen E. Spurgeon , et al. · 2024

Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertensi…

<span>T‐cell</span> prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments Open

Victoria A. Vardell, Daniel A. Ermann, Lindsey Fitzgerald, Harsh Shah, Boyu Hu , et al. · 2024

Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critica…

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes Open

Charlotte B Wagner, Kenneth M. Boucher, Adrienne Nedved, Ivana N. Micallef, Sanjal H. Desai , et al. · 2023

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most…

Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia Open

Victoria A. Vardell, Daniel A. Ermann, Lindsey Fitzgerald, Harsh Shah, Boyu Hu , et al. · 2023

Overall survival for chronic lymphocytic leukemia (CLL) patients by race; propensity score matched by age, Charlson-Deyo comorbidity score, insurance, and income and education level of zip code of residence.

Influence of Racial and Ethnic Identity on Overall Survival in Patients with Chronic Lymphocytic Leukemia Open

Victoria A. Vardell, Daniel A. Ermann, Lindsey Fitzgerald, Harsh Shah, Boyu Hu , et al. · 2022

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with the highest incidence in the White, non-Hispanic population. To better understand underrepresented minority CLL patients, patients diagnosed with CLL from 2004-2…

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma Open

Harsh Shah, Victoria A. Vardell, Erin Hickey, Amanda Fegley, Kalub Fedak , et al. · 2022

Table 1: Baseline Characteristics of CT and NT cohortsFigure 1: Comparison of EFS between CT and NT cohorts Background: Novel agents such as brentuximab vedotin (BV) and check-point inhibitors (CPIs) have high response rates in patients wi…

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions Open

Ajay Major, Edward R. Scheffer Cliff, Daniel A. Ermann, Urshila Durani, David A. Russler‐Germain · 2022

In the POLARIX trial, pola‐R‐CHP demonstrated improved progression‐free survival (PFS) compared to R‐CHOP in untreated intermediate‐ to high‐risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including…

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA Open

Daniel A. Ermann, Victoria A. Vardell, Erin Hickey, Amanda Fegley, Dipenkumar Modi , et al. · 2022

Background: Traditional salvage chemotherapy followed by autologous stem cell transplant (ASCT) is the standard second line approach for treatment of relapsed/refractory (r/r) Classical Hodgkin Lymphoma (cHL) and can cure approximately 50-…

P675: TREATMENT OF HYPERTENSION IN PATIENTS RECEIVING BTK INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY Open

M. Shadman, J. Voutsinas, Bahjat Fakhri, S. Khajavian, S. Spurgeon , et al. · 2022

Background: Hypertension (HTN) is an adverse event (AE) associated with the use of ibrutinib and less commonly with second generation BTK inhibitors (BTKis) as shown by a significant lower rate of HTN with acalabrutinib compared to ibrutin…

Multiple Myeloma Patients Treated at Academic Centers have Improved Survival Outcomes Open

Victoria A. Vardell, Daniel A. Ermann, Srinivas K. Tantravahi, Brian McClune, Mary Steinbach , et al. · 2021

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma Open

Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, Randa Tao, David K. Gaffney , et al. · 2021

By Daniel A. Ermann, Victoria A. Vardell & 5 more. Whether the addition of RT provided a survival benefit in early-stage DLBCL patients based on primary site at presentation comparing nodal to EN disease.

Primary Thyroid Lymphoma: An Analysis of the National Cancer Database Open

Victoria A. Vardell, Daniel A. Ermann, Emily K. Griffin, Peter T. Silberstein · 2019

Introduction Primary thyroid lymphoma (PTL) is a rare malignancy, representing only 1% to 5% of thyroid malignancies and 2.5% to 7% of all extranodal lymphomas. Most cases of PTL are of B-cell origin, and 98% of all PTL cases are non-Hodgk…

Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. Open

Daniel A. Ermann, Victoria A. Vardell, Hafiz Muhammad Fazeel, Brittany C. Thomas, Peter T. Silberstein · 2019

Prostatic leiomyosarcoma is an aggressive malignancy with a high risk of metastasis and a poor prognosis that poses unique diagnostic and treatment challenges.

Daniel A. Ermann YOU? Author Swipe